São Paulo's Second Regional Labor Court (TRT-2) authorized GPA to pay R$ 140 million in labor execution claims in up to 72 monthly installments—debts that, without the plan, would have had to be paid out in full by the end of 2027. For PCAR3 shareholders, the news is positive for cash flow and neutral for fundamentals: the company's structural problems do not disappear with an installment plan.
PCAR3: What Is GPA's Stock?
PCAR3 is the ticker for Companhia Brasileira de Distribuição shares traded on the B3—the company behind the Pão de Açúcar and Extra supermarket chains. Assaí, which used to be the group's cash-and-carry wholesale arm, was spun off years ago and now operates independently. What remains under PCAR3 is the neighborhood retail business (premium supermarkets and hypermarkets) with R$ 17.8 billion in net revenue over the last twelve months and a restructuring liability that dominates any analysis of the company.
Since early 2026, GPA has been going through an extrajudicial reorganization process to renegotiate R$ 4.568 billion in non-operating debt—a plan approved by a São Paulo court in October that put the company on a path of slow, step-by-step reorganization. The PEPT labor payment plan approved on November 19 is another step up that ladder.
What Did TRT-2 Approve and Why Was It a Problem Before?
PEPT (the Special Labor Payment Plan) is a mechanism that groups ongoing labor lawsuits into a single structured payment schedule. The Special Body of TRT-2, which covers the city of São Paulo, released its approval decision on November 19, 2026. Without this plan, GPA would have needed to pay the full amount of these claims by the end of 2027—a concentrated cash outflow for a company still executing its broader restructuring.
With the installment plan, the liabilities are spread out over up to six years, adjusted by the Selic interest rate. The final financial cost will be higher than the original balance, but the company gains something more valuable right now: predictability. In a material fact filing sent to CVM, Brazil's securities regulator, GPA stated that the approval "will allow the Company to better manage its labor liabilities, providing greater predictability in its payment flow and the opportunity to negotiate individual settlements to reduce obligations." These individual settlements are important because they can lower the total amount owed over the course of the plan.
Under execution at the court; without the plan, it was due by the end of 2027
Monthly payments starting from approval, adjusted by the Selic rate
Of the total R$ 4.568 billion under restructuring—PEPT solves one step, not the whole staircase
Two Courts Still Pending—How Much Additional Relief Could Come?
The TRT-2 PEPT is not the only one in progress. GPA reported that it is discussing similar arrangements in the 10th Region Labor Court (covering the Federal District and Tocantins) and the 15th Region Labor Court (covering inland São Paulo), where injunctions have suspended payments while negotiations move forward. The company did not disclose the value of the claims in these two courts in its material fact filing. Once approved, the data will be released in a CVM filing, providing a new figure to measure the cumulative relief on labor liabilities.
Additionally, GPA announced that it is updating its accounting provisioning methodology for processes covered by PEPT and other labor lawsuits. In practice, this could lead to adjustments in provisions over the coming quarters—upward or downward, depending on how individual settlements progress under the plan. The company has not yet provided an estimate for the expected accounting impact. To understand how the 21st debenture issuance of R$ 112 million and the extrajudicial reorganization plan affected the balance sheet, the Q4 2026 report (scheduled for release in 2027) will be the next checkpoint.
PCAR3: Buy or Sell After PEPT?
The site's verdict on PCAR3, calculated using the stock price of R$ 2.99 on November 18, 2026, is avoid. Its fundamentals score is 2.1 out of 10—the result of recurring net losses, high leverage, and tight margins. Over the past twelve months, the company generated R$ 17.8 billion in revenue with an EBITDA margin of just 3.54% and a net loss of R$ 2.99 billion. The Q3 2026 earnings report showed a loss of R$ 220 million from continuing operations—even after management actively worked to cut expenses, indicating that the problem is not merely temporary.
The PEPT installment plan is positive for cash flow—it avoids a concentrated cash drain in 2027 and improves payment visibility. However, it does not alter the two core problems defining the investment thesis: leverage standing at 5.93x net debt-to-EBITDA and an operational loss cycle that has yet to reverse. The estimated fair value is R$ 8.76 with low confidence, meaning the model acknowledges room for error in the valuation—not that the stock is necessarily cheap. Anyone who bought in during the peak euphoria of the October court approval and expected a quick turnaround needs to adjust that timeline.
- Real cash flow relief: without PEPT, R$ 140 million would have left the company all at once by 2027; payments are now spread over up to six years
- Opens the door for individual settlements with workers, with the potential to reduce total cash outflows
- TRT-10 and TRT-15 still pending—if approved, they will expand labor liability relief
- Extrajudicial reorganization plan approved in October: the main restructuring has court backing and is moving forward
- Adjusted by the Selic rate: the cumulative financial cost over 72 months will exceed the original balance
- Leverage of 5.93x remains far above what food retail typically tolerates without compromising operations
- Recurring operating losses: the company has not yet reached breakeven in its day-to-day operations
- PEPT covers ~3% of the total restructured amount—the problem is structural; this news does not change the scale of the recovery
If you already hold PCAR3, PEPT is favorable news for the cash flow calendar: it removes pressure that would have hit in 2027 and opens room for individual negotiations. However, GPA's turnaround thesis depends on bigger items—leverage needs to fall below 4x, operational margins must return to sustainable territory, and the R$ 4.5 billion restructuring plan must be executed without stumbles. For investors on the sidelines considering a position: the risk remains high; the labor installment plan has not changed the return premium or the confidence in the estimated fair value.
TRT-10 and TRT-15—monitor GPA's material fact filings; when the plans in these two courts are approved (or denied), a CVM disclosure will detail the amount at stake and the new payment schedule
Expense reduction (target of R$ 415 million in 2026)—if Q4 2026 confirms the cost-cutting guidance, leverage will begin to decline; this data will be released in the first-quarter 2027 earnings report
Leverage below 4x—the current level is 5.93x net debt-to-EBITDA; while it remains above 4x, the risk of restructuring execution failure is high and the turnaround thesis remains fragile
The TRT-2 PEPT is welcome, punctual news for GPA's cash flow—R$ 140 million that will not leave all at once in 2027, creating room for reduction agreements. However, it does not change the verdict on PCAR3: the company is undergoing heavy restructuring, leverage sits at 5.93x, and operating losses are recurring. Investors tracking the turnaround thesis have a new data point in their favor; those evaluating an entry still face high risk and should wait for clear signs of recovering fundamentals before acting.